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ABSTRACT
Background and Objectives: Atrial high-rate episodes (AHREs) can be continuously 
detected by cardiovascular implantable electronic devices (CIEDs); however, the predictors of 
clinically relevant AHREs are unclear.
Methods: This prospective multicenter study monitored 816 patients (median age 73 years, 
40.4% male) without atrial fibrillation (AF) from September 2017 to July 2020. AHREs was 
defined as a programmed atrial detection rate >220 beats/min. The reference values of 6 
minutes and 6 hours were set to analyze clinical implication of AHREs based on previously 
published data that the 6 minutes excluded most episodes of oversensing.
Results: During a median follow-up of 18 months (interquartile interval 9–26 months), 
AHREs with the longest durations of >15 seconds, >6 minutes, and >6 hours and clinically 
documented AF by electrocardiography were noted in 246 (30.1%), 112 (13.7%), 49 (6.0%), 
and 24 (2.9%) patients, respectively. Among patients developing AHREs >6 minutes, 102 
(91.1%) of 112 patients were identified at the 6-month visit. Patients with AHREs >6 minutes 
had higher proportions of sick sinus syndrome, subjects with atrial premature beat >1% on 
Holter monitoring, and larger left atrium (LA) size than patients with AHREs ≤6 minutes. 
Multivariable logistic regression analysis showed that LA diameter >41 mm (odds ratio [OR], 
2.08; 95% confidence interval [95% CI], 1.25–3.45), and sick sinus syndrome (OR, 3.22; 95% 
CI, 1.91–5.43) were associated with AHREs >6 minutes.
Conclusions: In patients with LA diameter >41 mm, and sick sinus syndrome before CIEDs 
implantation is associated with risk of developing AHREs >6 minutes.
Trial Registration: ClinicalTrials.gov Identifier: NCT03303872
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INTRODUCTION
Cardiac implantable electronic devices (CIEDs) can be programmed to monitor and identify 
atrial high-rate episodes (AHREs), also described as “subclinical atrial fibrillation (SCAF),” 
which is defined as asymptomatic atrial fibrillation (AF), atrial tachycardia (AT), and atrial 
flutter (AFL) of short duration. Individuals may benefit from using CIEDs to detect AHREs 
as increasing evidence indicates that AHREs are associated with stroke risk. However, 
the expected stroke risk in patients with AHREs was much lower than that in clinically 
documented AF patients with similar risk profile.1-5) Most studies used an episode duration 
longer than 5–6 min to define AHREs,3)6-10) although a reported false-positive rate of 17.3%, 
making physician review more essential compared with AHREs lasting >6 hours, a false-
positive rate of 3.3%.11) Current guidelines on non-valvular AF recommend anticoagulation 
therapy in patients with CHA2DS2-VASc scores ≥2 and consideration of anticoagulation 
therapy in patients with CHA2DS2-VASc scores of 1.12)13) Recently, the European Heart Rhythm 
Association suggested consideration of anticoagulation therapy for patients with AHREs 
>5.5 hours and with two additional stroke risk factors.14) However, the optimal primary stroke 
prevention indication and strategy remain uncertain.
Previous studies have reported various predictors of AHREs in patients with CIEDs. In 
the ASSERT study,1) lower resting heart rate and sinus node disease were associated with 
the prediction of AHREs. Other studies reported that a history of heart failure predicted 
AHREs,9) while others reported that a history of recurrent transient ischemic attack (TIA) 
and heart failure (HF),15) increased age, increased left atrium (LA) size, and lower systolic 
blood pressure predicted AHREs.16) A meta-analysis including 10 studies found that baseline 
characteristics; diabetes mellitus (DM); old age; thromboembolism events; congestive 
heart failure, hypertension (HTN), age ≥75 years, DM, stroke, CHADS2 score; and coronary 
artery disease (CAD) were not associated with the prediction of AHREs.17) Therefore, AHREs 
predictors have not been well established and the optimal treatment for preventing stroke 
primarily in AHREs is uncertain. Thus, the aim of the present study was to prospectively 
investigate clinical predictors for AHREs and evaluate the clinical development of AF and 
cardiovascular events according to the presence of AHREs.
METHODS
Study design and methods
The evaluation of AF occurrence in sick sinus syndrome and atrioventricular node disease 
patients after pacemaker implantation (AF-Pacemaker Study) was a prospective, multicenter, 
observational study performed in patients with AF aged >18 years attending any of the 11 
tertiary hospital centers comprising all geographical regions of Korea. The study enrollment 
period started in September 2017 and ended in July 2020.
The AF-pacemaker study aims to investigate the occurrence and management (including 
ablation therapy) of device-detected AF/AT episodes in patients with post-pacemaker 
implantation through a prospective, non-randomized, non-blinded, observational, 
multicenter design. The study is conducted in compliance with the ethical rules of the 
Declaration of Helsinki (2013) as a statement of ethical principles for medical research 
involving human subjects by The World Medical Association and approved by the 
Institutional Review Board of Yonsei University Health System (1-2017-0008). This study 
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is registered at ClinicalTrials.gov (NCT03303872). The Ethics Committees of all 11 tertiary 
hospital centers (Severance Hospital, Seoul National University Bundang Hospital, Seoul 
National University Hospital, Donga University Medical Center, Keimyung University 
Hospital, Ewha Womans University Medical Center, Daegu Catholic University Medical 
Center, Korea University Medical Center, Eulji University Hospital, CHA Bundang Medical 
Center, and Kangneung Asan Medical Center) approved this study, and all patients provided 
informed consent for their inclusion.
Study population
The study population included patients 1) eligible for permanent pacemaker implantation 
based on the 2016 revised Korean indication guideline on cardiac pacemaker implantation, 
2) with an estimated atrial pacing percentage >40% under sinus rhythm (Lower rate ≥60 
bpm, close hysteresis, and rest rate), 3) estimated ventricular pacing percentage >40% under 
sinus rhythm (lower rate ≥40 bpm, dual chamber pacing, close hysteresis, and rest rate). 
Data collection was usually conducted by personnel with no clinical activity assigned to the 
project. Data were entered into a common electronic database to limit inconsistencies and 
errors and provided online help for key variables. Each center could see its data and those of 
the other participating centers.
A total of 816 consecutive patients were enrolled at 11 tertiary centers and implanted with 
a St. Jude Medical dual-chamber rate-adaptive pacemaker (Assurity PM2240) with stored 
electrogram capabilities for sick sinus syndrome (sinus bradycardia, sinus pause ≥3 seconds, 
tachy-brady syndrome, sinus node dysfunction, and chronotropic incompetence) or 
atrioventricular block (high degree/complete atrioventricular block). Patients were eligible 
for inclusion in the study if they were at least 19 years of age and were available for periodic 
observation after pacemaker implantation. We excluded patients with severe liver dysfunction 
(aspartate transaminase/alanine transferase ≥3 times the normal upper limit), severe renal 
dysfunction (serum creatinine ≥3.5 mg/dL or creatinine clearance ≤30 mL/min) including 
dialysis, pregnant, lactating, or with malignant cancer, dilated cardiomyopathy, hypertrophic 
cardiomyopathy, severe valvular heart disease, or life expectancy ≤12 months from enrollment. 
Patients were also excluded if they had AF at baseline before pacemaker (Figure 1).
Baseline assessment and patient follow-up
We collected data on each patient's baseline demographic characteristics, clinical 
information, 12-lead electrocardiogram (ECG), laboratory examination, medications, 
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AHREs detection, n=370
AHREs ≤6 min, n=258 (70%) AHREs >6 min, n=112 (30%)
Eligible 816 patients
• Enrolled between September 2017 and July 2020
• No history of AF or AFL
• Primary indication: sick sinus syndrome or AV node disease
• Pacemaker clinic follow-up: at least >3 mon after implantation
Figure 1. Flow diagram showing study participants. 
AF = atrial fibrillation; AFL = atrial flutter; AHRE = atrial high rate episode; AV = atrioventricular.
Holter monitoring, treadmill test, and transthoracic echocardiography before pacemaker 
implantation. The baseline AF rhythm for patient exclusion was reviewed from documented 
AF on surface ECG/Holter/treadmill test. Device interrogation information was obtained 
from a clinic visit at 6, 12, and 18 months after pacemaker implantation. There was allowed 
up to 3 months before and after each clinic visit interval. The AHREs were interrogated to 
compare ECG traces and pacemaker AHREs data at the end of the ambulatory monitoring 
period. The clinicians were blinded to the results of the atrial diagnostic data. A Clinical 
Events Committee classified causes of death and adjudicated all suspected clinical events 
with blinding to indications of pacemaker implantation. An ECG Core Laboratory reviewed 
the ECGs and confirmed AF diagnoses.
Pacemaker programming and AHREs detection
The pacemakers incorporated bipolar atrial and ventricular leads (Tendril MRI LPA1200M, 
Isoflex Optim 1944/1948, Tendril ST Optim 1888TC) in all patients. The atrial and ventricular 
leads were placed in the right atrial appendage and right ventricular apex, respectively. An 
AHREs detection rate of 220 beats/min was programmed and storage of up to four atrial 
electrograms of 12-second duration on automatic detection of AHREs was activated. At every 
visit, the longest durations of all AHREs were ascertained. The longest AHREs durations 
were classified >15 vs. ≤15 seconds, >6 vs. ≤6 minutes, and >6 vs. ≤6 hours. Clinical events 
including cerebrovascular accidents (CVAs), major/minor bleeding, myocardial infarction 
(MI), and all-cause deaths were recorded.
Statistical analysis
Continuous variables were presented as mean±standard deviations for normally distributed 
values or medians and interquartile interval (IQI) for non-normally distributed values and 
categorical variables as numbers and percentages in each group. The baseline characteristics 
of the two groups were compared using Student's t- or Mann–Whitney U-tests for continuous 
variables and Pearson's χ2 or Fisher's exact tests for categorical variables. We used a logistic 
regression model for multivariate analysis to assess predictors of AHREs after adjusting for 
other clinical events. Based on age, sex, and body mass index (BMI), we built a multivariate 
logistic model by adding variables that were p values <0.10 into the univariate models. 
Logistic regression analysis was also used to confirm the statistical significance between 
AHREs predictors and longest duration. Associations were presented as odds ratios (ORs) 
with 95% confidence intervals (CIs). All analyses were performed using SAS version 9.4 (SAS 
Institute) and R version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria). 
Two-tailed p values <0.05 indicated statistical significance.
RESULTS
Between September 2017 and July 2020, this study enrolled 816 patients with a median 
follow-up of 18 months. The median patient age was 73 (65, 79) years and 60% were women. 
Atrioventricular block (58.1%) was the most common indication for CIEDs implantation, 
followed by sick sinus syndrome (41.9%). The median CHA2DS2-VASc score was 3 (2, 4); 677 
(83.0%) of patients had scores ≥2 and 66.9% had hypertension. The median LA diameter was 
40 mm (36, 45), the left ventricular ejection fraction (LVEF) was 65% (60, 70) by transthoracic 
echocardiography, and the PR interval was 184 ms (164, 204) by electrocardiography. Fifty-
five (7.1%) showed atrial premature contraction (APC) at >1% per 24 hours. Overall, 358 
(43.9%) patients were taking renin-angiotensin-aldosterone system inhibitors (Table 1).
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Table 1. Baseline characteristics of the overall population (n=816)
Variables Values
Age (years) 73 (65, 79)
Male, No. (%) 329 (40.4)
Body mass index (kg/m2) 24.1 (22.1, 26.2)
Systolic blood pressure (mmHg) 135 (121, 147)
Diastolic blood pressure (mmHg) 71 (64, 80)














Age ≥75 years 364 (44.6)
Diabetes 228 (27.9)
Prior stroke/TIA 85 (10.4)




Estimated GFR (mL/min/1.73 m2) 77.6 (62.0, 91.6)
Free T4 (ng/dL) 1.1 (1.0, 1.3)
TSH (µIU/mL) 1.9 (1.1, 3.2)
Echocardiography
LA diameter (mm) 40 (36, 45)
LVEF (%) 65 (60, 70)
E/Em 11.6 (8.9 14.9)
Electrocardiogram
PR interval (ms) 184 (164, 204)
QRS duration (ms) 108 (90, 144)
QTc interval (ms) 455 (422, 488)
Medications
ARB/ACEi 358 (43.9)
Beta blocker 122 (15.0)




APC >1% 58 (7.1)
VPC >1% 54 (6.6)
Pacemaker indication
Sick sinus syndrome 342 (41.9)
AV block 474 (58.1)
The data are presented as number (%), mean±standard deviation, or median (interquartile interval). Non-
parametric continuous variables, as assessed using the Kolmogorov–Smirnov method, were analyzed using the 
Mann–Whitney U test.
ACEi = angiotensin-converting-enzyme inhibitor; AF = atrial fibrillation; APC = atrial premature complex; ARB = 
angiotensin receptor blocker; AV = atrioventricular; BUN = blood urea nitrogen; CHF = congestive heart failure; 
CKD = chronic kidney disease; E/Em = the ratio of the early diastolic mitral inflow velocity (E) to the early 
diastolic mitral annular velocity (Em); GFR = glomerular filtration rate; LA = left atrium; LVEF = left ventricular 
ejection fraction; QTc = corrected QT; TIA = transient ischemic attack; TSH = thyroid-stimulating hormone; VPC = 
ventricular premature complex.
*The CHA2DS2-VAS score is a measure of the risk of stroke in patients with atrial fibrillation, with scoring ranging 
from 0 to 9 and higher scores indicating greater risk. Congestive heart failure, hypertension, age 75 years or older 
(doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 years, sex category (female).
AHRE duration criteria
Analysis of the longest AHREs durations showed large variability (Supplementary Table 1). 
Using the AHREs cut-off, AHREs >6 minutes were identified in 102 (12.5%) patients between 
enrollment and the 6-month follow-up and 112 (13.7%) patients during the entire study period. 
Longest AHREs lasting >6 hours were found in 34 (4.2%) patients between enrollment and the 
6-month follow-up, and 49 (6.0%) patients during the entire study period. Overall, 24 (2.9%) 
of the 816 patients experienced newly developed AF, as documented by 12-lead ECG during the 
follow-up period. In patients with confirmed AHRE, the most AHRE was observed within 6 
months after pacemaker implantation. In contrary, more than half of the patients diagnosed 
with newly detected AF were identified more than 6 months after implantation (Figure 2).
Patient characteristics: longest AHREs duration >6 minutes versus ≤6 minutes
Comparison of the baseline characteristics at the time of CIEDs implantation between 
the groups with AHREs ≤ or >6 minutes is shown in Table 2. These patients did not differ 
significantly with respect to age, sex, BMI, estimated glomerular filtration rate, thyroid 
function, LVEF, E/Em, PR interval, history of smoking, alcohol consumption, proportion of 
congestive heart failure, HTN, DM, prior stroke/TIA, vascular disease, CHA2DS2-VAS score, 
chronic kidney disease, and dyslipidemia. Medication use including renin-angiotensin-
aldosterone system inhibitors, calcium channel blockers, statins, and diuretics also did 
not differ significantly between patients with longest AHRE durations >6 and ≤6 minutes. 
Patients with the longest AHREs durations >6 minutes had larger LA diameter, a higher 
proportion of APC >1% on Holter monitoring, beta-blockade use, and sick sinus syndrome 
among CIEDs implantation indications compared to patients with longest AHREs duration 
≤6 minutes. Comparison based on a longest AHREs duration cut-off of 6 hours showed 
relatively differences in LA diameter and proportion of prior stroke/TIA, APC >1% on Holter 
monitoring, beta-blockade use (Table 3).
Predictors of longest AHREs duration >6 minutes
During the follow-up period, 112 of the 816 (13.7%) patients had AHREs with a longest 
duration >6 min. Univariate logistic regression analysis showed that LA diameter >41 mm (OR, 
2.05; 95% CI, 1.29–3.28; p=0.003), APC >1% on Holter monitoring before CIEDs implantation 
(OR, 3.14; 95% CI, 1.46–6.78; p=0.004), and sick sinus syndrome for CIEDs implantation (OR, 
3.85; 95% CI, 2.42–6.14; p<0.001) predicted a higher probability of longest AHREs duration 
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Enrollment~6 mon clinic visit
6 mon clinic visit~
Figure 2. Distributions of cardiac implantable electronic device-detected AHREs, and clinical AF during study period. 
AF = atrial fibrillation; AHRE = atrial high rate episode.
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Table 2. Baseline characteristics for longest AHRE duration ≤6 min (n=258) versus >6 min (n=112)
Variables AHRE ≤6 min (n=258) AHRE >6 min (n=112) p value
Age (years) 73 (65–78) 74 (67–80) 0.358
Male 102 (39.5) 48 (42.9) 0.629
Body mass index (kg/m2) 24.0 (22.3–26.0) 23.9 (22.1–26.1) 0.532
Systolic blood pressure (mmHg) 136 (124–150) 133 (120–145) 0.064
Diastolic blood pressure (mmHg) 71 (65–80) 70 (63–80) 0.328
Heart rate (/min) 60 (50–74) 60 (50–72) 0.595
Smoking 0.539
Never 209 (81.0) 92 (82.1)
Former/current 49 (19.0) 20 (17.8)
Alcohol 0.558
Never 202 (78.3) 90 (80.3) 1.000
Former/current 56 (21.7) 22 (19.7)
CHA2DS2-VAS score* 3 (2, 4) 3 (2, 4) 0.611
CHA2DS2-VAS score, group 0.924
0 8 (3.1) 4 (3.6)
1 38 (14.7) 15 (13.4)
≥2 212 (82.2) 93 (83.0)
CHF 8 (3.1) 3 (2.7) 1.000
Hypertension 177 (68.6) 72 (64.3) 0.488
Age ≥75 years 116 (45.0) 54 (48.2) 0.643
Diabetes 69 (26.7) 25 (22.3) 0.443
Prior stroke/TIA 26 (10.1) 17 (15.2) 0.219
Vascular disease 20 (7.8) 13 (11.6) 0.319
CKD 22 (8.5) 10 (8.9) 0.925
Dyslipidemia 76 (29.5) 27 (24.1) 0.572
Laboratory findings
Estimated GFR (mL/min/1.73 m2) 81.3 (65.1–95.0) 79.5 (62.0–89.0) 0.200
Free T4 (ng/dL) 1.2 (1.0–1.3) 1.1 (1.0–1.4) 0.602
TSH (µIU/mL) 1.8 (1.0–3.2) 2.0 (1.0–3.3) 0.611
Echocardiography
LA diameter (mm) 40 (35–45) 42 (37–45) 0.034
LVEF (%) 67 (60–71) 65 (60–70) 0.380
E/Em 11.0 (8.4–14.5) 11.4 (8.3–14.8) 0.601
Electrocardiogram
PR interval (ms) 184 (167–207) 184 (163–207) 0.469
QRS duration (ms) 112 (90–144) 98 (88–134) 0.150
QTc interval (ms) 455 (425–488) 451 (421–477) 0.304
Medications
ARB/ACEi 116 (45.0) 42 (37.5) 0.223
Beta blocker 27 (10.5) 28 (25.0) 0.001
Calcium channel blocker 81 (31.4) 31 (27.7) 0.554
Statin 96 (37.2) 43 (38.4) 0.921
Diuretics 54 (20.9) 25 (22.3) 0.871
Holter recording
APC >1% 13 (5.0) 16 (14.3) 0.005
VPC >1% 14 (5.4) 11 (9.8) 0.186
Pacemaker indication <0.001
Sick sinus syndrome 80 (31.0) 71 (63.4)
AV block 178 (69.0) 41 (36.6)
The data are presented as number (%) or median (interquartile interval). Non-parametric continuous variables, as assessed using the Kolmogorov–Smirnov 
method, were analyzed using the Mann-Whitney U test.
ACEi = angiotensin-converting-enzyme inhibitor; AHREs = atrial high rate episodes; APC = atrial premature complex; ARB = angiotensin receptor blocker; AV = 
atrioventricular; BUN = blood urea nitrogen; CHF = congestive heart failure; CKD = chronic kidney disease; E/Em = the ratio of the early diastolic mitral inflow 
velocity (E) to the early diastolic mitral annular velocity (Em); GFR = glomerular filtration rate; LA = left atrium; LVEF = left ventricular ejection fraction; QTc = 
corrected QT; TIA = transient ischemic attack; TSH = thyroid-stimulating hormone; VPC = ventricular premature complex.
*The CHA2DS2-VAS score is a measure of the risk of stroke in patients with atrial fibrillation, with scoring ranging from 0 to 9 and higher scores indicating greater 
risk. Congestive heart failure, hypertension, age 75 years or older (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 years, sex category 
(female).
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Table 3. Baseline characteristics for longest AHRE duration ≤6 hours (n=321) versus >6 hours (n=49)
Variables AHREs ≤6 hours (n=321) AHREs >6 hours (n=49) p value
Age (years) 73 (66–79) 75 (67–79) 0.621
Male 127 (39.6) 23 (46.9) 0.410
Body mass index (kg/m2) 24.0 (22.2–25.9) 24.4 (22.5–26.5) 0.598
Systolic blood pressure (mmHg) 136 (123–149) 130 (117–142) 0.170
Diastolic blood pressure (mmHg) 72 (65–80) 70 (63–77) 0.190
Heart rate (/min) 62 (50–75) 62 (51–74) 0.933
Smoking 0.881
Never 264 (82.2) 41 (83.6)
Former/current 57 (17.8) 8 (16.4)
Alcohol 0.560
Never 266 (82.9) 40 (81.6)
Former/current 55 (17.1) 9 (18.4)
CHA2DS2-VAS score* 3 (2–4) 3 (2–5) 0.155
CHA2DS2-VAS score, group 0.573
0 11 (3.4) 1 (2.0)
1 48 (15.0) 5 (10.2)
≥2 262 (81.6) 43 (87.8)
CHF 8 (2.5) 3 (6.1) 0.346
Hypertension 215 (67.0) 34 (69.4) 0.864
Age, ≥75 years 144 (44.9) 26 (53.1) 0.358
Diabetes 85 (26.5) 9 (18.4) 0.299
Prior stroke/TIA 31 (9.7) 12 (24.5) 0.005
Vascular disease 26 (8.1) 7 (14.3) 0.252
CKD 27 (8.4) 5 (10.2) 0.189
Dyslipidemia 92 (28.7) 11 (22.4) 0.509
Laboratory findings
Estimated GFR (mL/min/1.73 m2) 80.7 (64.4–94.0) 81.0 (60.8–91.0) 0.634
Free T4 (ng/dL) 1.1 (1.0–1.3) 1.1 (1.0–1.4) 0.840
TSH (µIU/mL) 1.7 (1.0–3.1) 2.2 (1.2–4.6) 0.209
Echocardiography
LA diameter (mm) 40 (35–45) 42 (39–45) 0.149
LVEF (%) 66 (60–70) 65 (60–70) 0.838
E/Em 11.0 (8.1–14.3) 11.8 (8.9–16.2) 0.366
Electrocardiogram
PR interval (ms) 185 (166–208) 180 (164–204) 0.286
QRS duration (ms) 111 (90–143) 94 (86–122) 0.102
QTc interval (ms) 455 (424–488) 451 (425–476) 0.292
Medications
ARB/ACEi 135 (42.1) 23 (46.9) 0.625
Beta blocker 47 (14.6) 8 (16.3) 0.926
Calcium channel blocker 97 (30.2) 15 (30.6) 1.000
Statin 118 (36.8) 21 (42.9) 0.508
Diuretics 66 (20.6) 13 (26.5) 0.446
Holter recording
APC >1% 25 (7.8) 4 (8.2) 1.000
VPC >1% 21 (6.5) 4 (8.2) 0.908
Pacemaker indication 0.001
Sick sinus syndrome 120 (37.4) 31 (63.3)
AV block 201 (62.6) 18 (36.7)
The data are presented as number (%) or median (interquartile interval). Non-parametric continuous variables, assessed using the Kolmogorov–Smirnov 
method, were analyzed using Mann-Whitney U tests.
ACEi = angiotensin-converting-enzyme inhibitor; AHREs = atrial high rate episodes; APC = atrial premature complex; ARB = angiotensin receptor blocker; AV = 
atrioventricular; BUN = blood urea nitrogen; CHF = congestive heart failure; CKD = chronic kidney disease; E/Em = the ratio of the early diastolic mitral inflow 
velocity (E) to the early diastolic mitral annular velocity (Em); GFR = glomerular filtration rate; LA = left atrium; LVEF = left ventricular ejection fraction; QTc = 
corrected QT; TIA = transient ischemic attack; TSH = thyroid-stimulating hormone; VPC = ventricular premature complex.
*The CHA2DS2-VAS score is a measure of the risk of stroke in patients with atrial fibrillation, with scoring ranging from 0 to 9 and higher scores indicating a 
greater risk. Congestive heart failure, hypertension, age 75 years or older (doubled), diabetes, stroke (doubled), vascular disease, age 65 to 74 years, sex 
category (female).
>6 minutes. The sensitivity analysis of atrial pacing ratio rather than the diagnosis of sick sinus 
syndrome demonstrated consistent findings (Supplementary Table 2).
Multivariable logistic regression analysis demonstrated that LA diameter >41 mm (OR, 2.08; 
95% CI, 1.25–3.45; p=0.005), and prior sick sinus syndrome (OR, 3.22; 95% CI, 1.91–5.43; 
p<0.001) were significantly associated with the probability of AHREs with a longest duration 
>6 minutes (Table 4). Comparison of AHREs with a longest duration cut-off of 6 hours 
showed that prior stroke/TIA (OR, 1.62; 95% CI, 1.08–2.43; p=0.021), LA diameter >41 mm 
(OR, 1.96; 95% CI, 1.00–3.85; p=0.050), and sick sinus syndrome for CIEDs implantation 
(OR, 2.52; 95% CI, 1.27-4.99; p=0.008) were independently associated with longest AHREs 
duration >6 hours (Table 5).
Associations between AHREs and clinical outcomes
Total of four CVA events were observed during the study period. The incidence rates (IRs, 
percent per person-year) of CVA, major/minor bleeding, MI, and all-cause death were 2.30%, 
2.30%, 0%, and 0%, respectively, in patients with AHREs >6 minutes. For patients with 
AHREs ≤6 minutes, these IRs were 0.31%, 0.95%, 0.31%, and 0.31%, respectively. For the 
AHREs cut-off 6 hours, similar trends were observed (Supplementary Tables 3 and 4).
DISCUSSION
This study observed a substantial incidence in AHREs among patients 19 years of age or older 
with a history of sick sinus syndrome or atrioventricular node disease who had undergone 
pacemaker implantation and were free of clinical AF. AHREs with a longest duration >6 
minutes were detected in 12.5% of patients within 6 months after implantation and were 
detected at least once during a median follow-up period of 18 months in 13.7% of patients. 
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Table 4. Logistic regression analysis of factors associated with longest AHRE >6 min
Variables
Univariate analysis Multivariable analysis*
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Age 1.01 (0.99–1.03) 0.476 1.00 (0.98–1.03) 0.774
Male 1.15 (0.73–1.80) 0.550 1.36 (0.81–2.26) 0.244
Body mass index 0.98 (0.91–1.05) 0.508 0.95 (0.88–1.03) 0.236
Hypertension 0.82 (0.52–1.32) 0.416
Diabetes 0.79 (0.47–1.33) 0.370
Prior stroke/TIA 1.60 (0.83–3.08) 0.162
Vascular disease 1.56 (0.75–3.26) 0.235
CKD 1.05 (0.48–2.30) 0.900
Dyslipidemia 0.76 (0.46–1.27) 0.294
LA diameter 1.03 (0.99–1.07) 0.105
≤41 mm (reference)
>41 mm 2.05 (1.29–3.28) 0.003 2.08 (1.25–3.45) 0.005
LVEF 0.99 (0.96–1.02) 0.342
PR interval 1.00 (0.99–1.00) 0.205
APC at Holter monitoring
APC <1% (reference)
APC >1% 3.14 (1.46–6.78) 0.004 1.54 (0.67–3.54) 0.314
Pacemaker indication
AV block (reference)
Sick sinus syndrome 3.85 (2.42–6.14) <0.001 3.22 (1.91–5.43) <0.001
AHREs = atrial high rate episodes; APC = atrial premature contraction; AV = atrioventricular; CI = confidence interval; CKD = chronic kidney disease; ECG = 
electrocardiogram; LA = left atrium; LVEF = left ventricular ejection fraction; TIA = transient ischemic attack.
*Adjusted covariates include age, sex, body mass index, LA diameter >41 mm, APC >1% on Holter monitoring, pacemaker indication.
Episodes of subclinical atrial tachyarrhythmias were almost five times as common as episodes 
of clinical AF. During the course of the study, AHREs detection was confirmed in all clinical 
AF patients. Clinical AF developed in 21.4% (24/112) of patients with longest AHREs duration 
>6 minutes and 48.9% (24/49) of patients with longest AHREs duration >6 hours, suggesting 
that there can be a gap between subclinical events and clinical detection. Larger LA size (>41 
mm) and sick sinus syndrome for CIEDs implantation were significant predictors of longest 
AHREs duration >6 minutes. By means of longest AHREs duration >6 hours, prior history of 
stroke or TIA, larger LA size (>41 mm), and sick sinus syndrome were significant predictors. 
However, we did not demonstrate a meaningful relationship between AHREs and clinical 
events including CVA, bleeding, MI, and all-cause death.
Most studies of patients with CIEDs have shown a high incidence of CIEDs-detected AH
REs.1)3)4)6)8)9)11)18)19) A growing body of clinical data supports the hypothesis that AHREs are 
associated with an elevated risk of developing further clinical AF and stroke; however, the stroke 
risk is relatively lower than that in patients with clinical AF due to the short and rare nature of 
AHREs.14) Data from ASSERT trial1) showed that AHREs lasting more than 6 min in the first 3 
months after CIED implantation were associated with a 5.6-fold increased hazard of clinical AF 
during a mean 2.5-year follow-up. Similar results were reported in the MOST trial,3) in which 
AHREs lasting at least 5 minutes were associated with a 5.9-fold increased hazard of clinical AF 
during median 2.3-year follow-up. Clinical atrial tachyarrhythmias on surface ECG occurred 
in 25.7% of patients in the MOST trial, 15.8% of patients in the ASSERT trial, and 28.9% of 
patients in the ASSERT II trial, which investigated patients ≥65 years of age.1)3)20) In subsets of 
ASSERT patients, older age, higher BMI, and longer AHRE episodes were associated with AF 
progression.21) In our study, 21.4% and 48.9% of patients with AHREs >6 minutes and >6 hours 
were confirmed to have clinically documented AF during follow-up. As the number of patients 
was small, we could not proceed with further analysis. Although AHREs are more likely to 
allow detection of ECG-documented AF, about 80% of patients with AHREs >6 minutes never 
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Table 5. Logistic regression of factors associated with AHREs (>6 hours)
Variables
Univariate analysis Multivariable analysis*
Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Age 1.01 (0.98–1.04) 0.631 1.00 (0.96–1.03) 0.757
Male 1.35 (0.74–2.47) 0.329 1.82 (0.93–3.54) 0.080
Body mass index 1.02 (0.93–1.12) 0.688 1.00 (0.90–1.12) 0.950
Hypertension 1.12 (0.58–2.14) 0.738
Diabetes 0.63 (0.29–1.34) 0.228
Prior stroke/TIA 3.03 (1.43–6.42) 0.004 1.62 (1.08–2.43) 0.021
Vascular disease 1.89 (0.77–4.63) 0.163
CKD 1.24 (0.45–3.38) 0.678
Dyslipidemia 0.71 (0.35–1.45) 0.349
LA diameter 1.02 (0.97–1.07) 0.375
≤41 mm (reference)
>41 mm 2.16 (1.14–4.10) 0.018 1.96 (1.00–3.85) 0.050
LVEF 0.99 (0.95–1.03) 0.597
PR interval 0.99 (0.98–1.00) 0.120
APC in Holter monitoring implantation
APC <1% (reference)
APC >1% 1.05 (0.35–3.17) 0.928
Pacemaker indication
AV block (reference)
Sick sinus syndrome 2.89 (1.55–5.38) 0.001 2.52 (1.27–4.99) 0.008
AHREs = atrial high rate episodes; APC = atrial premature contraction; AV = atrioventricular; CI = confidence interval; CKD = chronic kidney disease; ECG = 
electrocardiogram; LA = left atrium; LVEF = left ventricular ejection fraction; TIA = transient ischemic attack.
*Adjusted covariates include age, sex, body mass index, prior stroke/TIA, LA diameter >41 mm, pacemaker indication.
develop ECG-documented AF in the subsequent years, probably due to the infrequent and short 
nature of AHREs in most patients and missing link that we have not proven yet.
We detected four CVA events during the median 18-month follow-up. Our findings did not 
demonstrate an increased risk of CVA in patients with CIEDs developing AHREs. However, 
a meta-analysis of seven studies22) showed that AHREs were associated with a 2.4-fold 
increased risk of stroke. Although the definitions of AHREs duration varied significantly 
between studies, subsequent stratified analyses showed that most events occurred in patients 
with >24-hours AHREs.23) Therefore, the predominant evidence suggests a dose-response 
relationship between longest AHREs duration and stroke risk. Long-term follow-up is 
necessary to determine the relationship between AHREs and stroke risk in this registry.
The increased risk associated with developing AHREs may be similar to that for AF, 
reinforcing the concept that AHREs and AF are likely to represent a clinical continuum in 
the spectrum of atrial tachyarrhythmias. Some predictors for AHREs have been identified 
in patients with CIEDs. In the ASSERT trial,1) sinus node dysfunction and decreased resting 
heart rate were associated with the prediction of AHREs. Gonzales et al.9) reported that 
previous HF predicted AHREs, while Cheung et al.24) found that sinus node disease and a 
higher proportion of ventricular pacing were associated with AHREs. A meta-analysis of 
28 dual-chamber device studies showed that the clinical variables related to AF including 
increasing age, HTN, DM, CAD, embolic events, and CHADS2 were not associated with 
the prediction of AHREs. In our study, the independent predictors of AHREs with longest 
duration >6 minutes were larger LA size (>41 mm), and sick sinus syndrome before CIED 
implantation. Between patients who developed AHREs and those who did not, an LA size 
of 41 mm was a useful threshold to identify patients who would develop AHREs. Although 
total APC >1% on Holter monitoring showed predictive value for AHREs development 
in univariate analysis, this variable was not associated in the multivariate analysis. Prior 
stroke/TIA, LA diameter >41 mm, and sick sinus syndrome were the predictors for longest 
AHREs duration >6 hours. These differences may be explained in part by differences in the 
definitions of AHREs duration. Therefore, our data indicate new predictors including prior 
stroke/TIA and LA diameter >41 mm before CIEDs implantation.
This study has several limitations. First, although this was a prospective and multicenter 
study, the study design was non-randomized and observational. The study duration was 
relatively short compared to that in previous studies, the enrolled population was small, 
and additional potential confounding factors may have significantly affected the results. 
Second, the study population was limited to patients with pacemakers with generally 
normal LV systolic function. Therefore, the results cannot be directly applied to implantable 
cardioverter-defibrillator or cardiac resynchronization therapy populations, whose 
prevalence of CIEDs-detected AF may be higher. Third, although AHREs lasting >6 hours 
can improve the positive predictive value,11) current guidelines12) consider AHREs lasting >5 
minutes as clinically relevant, and the majority of studies3)6-10)used an episode duration of 
AHRE longer than 5–6 minutes. Therefore, it may be reasonable to analyze the results based 
on AHREs lasting >6 minutes. Finally, very few clinical events were observed during the 
follow-up period, including four cases of stroke. Patients are being enrolled and the follow-up 
period is relatively short; therefore, analysis of long-term data is required.
AHREs occurred frequently in patients with pacemakers who had a history of prior stroke/
TIA, LA diameter >41 mm, and sick sinus syndrome before CIEDs implantation but no 
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prior diagnosis of clinical AF. However, there was a lack of data regarding whether AHREs 
increased the stroke risk. More long-term follow-up data are required to determine the 
clinical impact of AHREs.
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